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Immune checkpoint inhibitors (antibodies that block the T cell co-inhibitory receptors
PD-1/PD-L1 or CTLA-4) have revolutionized the treatment of some forms of cancer. Impor-
tantly, combination approaches using drugs that target both pathways have been shown
to boost the efficacy of such treatments. Subsequently, several other T cell inhibitory
receptors have been identified for the development of novel immune checkpoint inhibitors.
Included in this list is the co-inhibitory receptor lymphocyte activation gene-3 (LAG-3),
which is upregulated on T cells extracted from tumor sites that have suppressive or
exhausted phenotypes.However, themolecular rules that govern the function of LAG-3 are
still not understood. Using surface plasmon resonance combined with a novel bead-based
assay (AlphaScreenTM), we demonstrate that LAG-3 can directly and specifically interact
with intact human leukocyte antigen class II (HLA-II) heterodimers. Unlike the homologue
CD4, which has an immeasurably weak affinity using these biophysical approaches, LAG-
3 binds with low micromolar affinity. We further validated the interaction at the cell sur-
face by staining LAG-3+ cells with pHLA-II-multimers. These data provide new insights
into the mechanism by which LAG-3 initiates T cell inhibition.
Keywords: cancer immunotherapy  immune checkpoint inhibitors  LAG-3  pHLA-II  T cells
 Additional supporting information may be found online in the Supporting Information sectionat the end of the article.
Introduction
Immune checkpoint inhibitors (ICIs; antibodies that block T cell
co-inhibitory receptors such as PD-1 and CTLA-4) have revolution-
ized the treatment of some cancers [1–3]. Combinations of these
ICIs targeting multiple pathways have demonstrated additional
efficacy in certain situations, [4], showing that these co-inhibitory
receptors can act through different mechanisms.
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Lymphocyte activation gene-3 (LAG-3) is a single pass trans-
membrane protein expressed on a proportion of different types
of immune cells including; αβ T cells, γδ T cells, NK cells, and
plasmacytoid dendritic cells. LAG-3 is upregulated upon activa-
tion of T cells and appears to act as a co-inhibitory receptor [5,6].
LAG-3 mediated suppression of T cell signaling has been shown
to be dependent on the three intracellular regions in the cytoplas-
mic tail [7], although the signaling pathway remains unknown.
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Localization of LAG-3 to the immune synapse is thought to be
mediated by an interaction with peptide-human leukocyte anti-
gens (pHLA-II) [8]. Indeed, LAG-3 binds preferentially to a sub-
set of HLA-II molecules expressed on membrane rafts on human
immature DC [9,10] and selectively recognizes stable complexes
of peptide and HLA-II [11]. LAG-3 expression has been impli-
cated in maintaining the function of Treg subsets such as classical
Foxp3+ Tregs [12]. In addition, LAG-3 expression, in conjunction
with CD49b, identifies a population of highly suppressive Foxp3-
regulatory cells termed type 1 regulatory (Tr1) cells [13]. These
Tr1 cells were present in tumor infiltrating lymphocytes (TILs)
extracted from human colorectal cancer patients [14] and from
liver tumors [15]. Together, these studies suggest LAG-3 expres-
sion may be associated with a sub-optimal immune response to
tumors, either through direct suppression of activated effector
responses or via the inhibitory effects of Treg populations.
Despite its well-established role in T cell regulation, little is
known about mechanisms by which LAG-3 mediates its biological
function. Although LAG-3 was first hypothesized to bind to
pHLA-II molecules in 1990 [16], a direct interaction between the
two molecules has not been formally demonstrated in the absence
of any other cell surface molecule interactions. Indeed, the idea
that LAG-3 bound to pHLA-II was first introduced because of the
sequence homology between CD4 and LAG-3, suggesting motifs
characteristic of four Ig-like domain containing proteins (Fig. 1).
CD4 is an extremely potent modulator of the immune response
yet has an affinity for HLA-II that is 100–1000-fold lower than
described for other cell surface interacting T cell proteins [17].
Hence, further understanding LAG-3 function entails under-
standing the binding of LAG-3 to HLA-II. Interactions between
LAG-3 and pHLA-II have so far been limited to cellular studies
using pHLA-II proficient and deficient cell lines, or with pHLA-II
blocking antibodies [8,18,19]. Although informative, it is difficult
to rule out the contributions of other molecules at the cell surface
in shaping these interactions [20,21]. Further experimental
evidence, showing that LAG-3 can block the pHLA-II-CD4 inter-
action, suggested that LAG-3 might bind to pHLA-II at a similar
site to CD4 [22,23], analogous to the characteristics of Ig-like
transcript 2 (ILT2) and CD8 that compete for binding to pHLA-I
[24–26].
Here, we characterized the direct interaction between LAG-
3 and pHLA-II using purified soluble proteins. We used a novel
biophysical technique (AlphaScreenTM) [27] as well as surface
plasmon resonance (SPR) to characterize the 1:1 binding affin-
ity of the interaction, and further demonstrated the interaction
between LAG-3 and pHLA-II by flow cytometry by staining stable
overexpressing JRT T3.5 Jurkat (JRT) LAG-3+ cells with pHLA-
II multimers. Our findings confirm that LAG-3 binds directly to
pHLA-II and suggests that this binding is independent of the HLA-
II allele or the presented peptide. The binding affinity measure-
ments have interesting implications for the mechanism of action
of this important T cell co-inhibitory receptor. Finally, these data
add to our understanding of LAG-3 biology and will help to guide
future therapeutic approaches that target this molecule.
Results
Direct LAG-3:Fc binding to pHLA-II detected by
AlphaScreenTM
Soluble LAG-3 was generated as a LAG-3:Fc fusion protein,
expressed in glycosylation-sufficient Chinese hamster ovary
(CHO) cells to form a functionally viable and stable protein dimer
as previously reported [19]. This dimer of LAG-3 has been used
extensively to explore LAG-3 function as a therapeutic agent [28].
Efforts were also made to generate a monomeric form of LAG-
3, but without success. In order to test the interaction between
Figure 1. (A) Domain arrangement as inferred from the LAG-3 protein sequence. Sequence analysis suggests LAG-3 possesses four extracellular Ig-
like domains (D1-D4), a single transmembrane domain (TM), and a short cytoplasmic tail (CT). D1 domain contains a V-type Ig-like domain (V) while
D2 to D4 contains C2-type Ig-like domains. (B) 2D schematic representation of LAG-3 D1 domain Ig-like sequence inferred domain organization.
The V-type domain contains an additional 30 amino acid (aa) “extra loop” sequence between C and C‘β-strands not characteristic of V-type Ig-like
domains. NH2=N-terminus, COOH=C-terminus. (C) Schematic overview of the hypothetic model of LAG-3 oligomerization and pHLA-II binding.
TM, transmembrane domain; CT, cytoplasmic tail domain
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Figure 2. (A) Schematic overview of
experimental setup for AlphaScreenTM
assays. (B) L243 binding to pHLA-DR1.
Assays used three concentrations of L243
antibody (0.3, 3, and 30 nM), titrated
against a one in three dilution series (0.3
to 300 nM) of pHLA-DR1. Data are rep-
resentative of three independent exper-
imental repeats using freshly prepared
beads. (C) LAG-3:Fc binding to pHLA-
DR1. Assays used three concentrations
of LAG-3:Fc (0.3, 3, and 30 nM), titrated
against a one in three dilution series
(0.3 to 300 nM) of pHLA-DR1. Data
are representative of three independent
experimental repeats using freshly pre-
pared beads. (D) LAG-3:Fc binding to
pHLA-DR1 and -DR4. Titration of pHLA-
DR1 and -DR4 in one in three dilu-
tion series (300 nM to 0.3 nM). Titration
of biotinylated HLA-A*02:01 (complexed
with the hTERT540-548 peptide) in a one
in three dilution series (300 nM to 0.3
nM) was used as a negative control. Data
are representative of three experimen-
tal repeats using freshly prepared beads.
(E) Cross titrations using LAG-3:Fc and
pHLA-DR1 using a one in three dilution
series (300 nM to 0.3 nM). Data are rep-
resentative of three biological repeats.
(F) AlphaScreenTM LAG-3:Fc/pHLA-DR1
blockade assay using anti-LAG-3 4B1
and anti-DR L243 fab fragments, IC50
= 1.32 nM. Data are inclusive of three
independent experimental repeats using
freshly prepared beads, error bars repre-
sent mean ± SEM.
LAG-3:Fc and pHLA-II, we produced soluble HLA-DRA1*
01:01/HLA-DRB*01:01 (HLA-DR1), and HLA-DRA1*01:01/HLA-
DRB*04:01 (HLA-DR4) using previously published methodology
[29, 30]. We initially chose a highly sensitive screening method,
Amplified Luminescent Proximity Homogeneous Assay Screen
(AlphaScreenTM) [27], to test the interaction between the LAG-
3:Fc and pHLA-II proteins [31]. AlphaScreenTM is a bead-based
protein–protein interaction detection assay in which, upon exci-
tation of a donor bead with low energy red-shifted light (680
nm), the photosensitizing phthalocyanines in the bead release
electronically excited singlet oxygen (1O2) molecules (Fig. 2A).
Singlet oxygen molecules can diffuse in solution up to 200 nm
(higher than 1−10 nm achieved with Forster resonance energy
transfer) due to their limited half-life. This results in a cascade of
anthracene rubrene and subsequent emission of light at 520−620
nm. A single donor bead releases up to 60 000 singlet oxygen
molecules, so the signal of one biological molecule to this bead
is highly amplified. This results in high sensitivity and a dynamic
range with very low background signal.
We first validated the AlphaScreenTM assay using pHLA-
DR1 and L243 (a well-characterized HLA-DR-specific antibody
that binds to conformationally intact heterodimers [32,33]).
AlphaScreenTM signal was detected in a concentration dependent
manner using a cross titration of pHLA-DR1 on donor beads,
and L243 on acceptor beads (Fig. 2B). AlphaScreenTM signal was
also detected in a concentration dependent manner using a cross
titration of either pHLA-DR1 or pHLA-DR4 on donor beads, and
LAG-3:Fc on acceptor beads (Fig. 2C and D). No binding was
detected when pHLA-A*02:01 (pHLA-A2) donor beads were used
(Fig. 2D). We confirmed these data using a larger range of accep-
tor bead protein concentrations (Fig. 2E; Supporting Information
Fig. S1). Of note, binding was detected even at low LAG-3 con-
centrations (0.3 nM), implying that the interaction might be of
relatively strong affinity. We also attempted to measure the inter-
action between pHLA-DR1 and CD4 but, consistent with the very
weak published affinity [17], we did not detect a signal (data not
shown). Finally, we demonstrated that the AlphaScreenTM sig-
nal detected through LAG-3:Fc binding to pHLA-DR1 could be
blocked using a LAG-3 specific antibody (Fig. 2F).
LAG-3 binds to pHLA-DR1 independently of the
peptide with low micromolar affinity
SPR analysis, using streptavidin immobilized pHLA-II and LAG-
3:Fc as the analyte (Fig. 3A), demonstrated specific (Fig. 3B),
concentration-dependent binding to HLA-DR1 complexed with
the HA309-318 peptide (Fig. 3C) and binding was not altered by the
expression system used to generate pHLA-DR1 or the presented
peptide (as shown by equal binding to pHLA-DR1 produced via a
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Figure 3. (A) Cartoon schematic describing formulation of SPR experiments performed using LAG-3:Fc as analyte injected over pHLA immobilized
sensor chips. FC, flow cell. (B) SPR analysis of LAG-3:Fc injection over immobilized HLA-A*02:01 complexed with the hTERT540-548 peptide. Senso-
grams reference subtracted from a blank no-ligand control flow cell. Data are representative of two independent experimental repeats (n = 2). (C)
SPR analysis showing concentration-dependent binding (57 μM to 0.11 μM) of LAG-3:Fc to HLA-DR1 produced from E. coli by in vitro refolding in the
presence of the HA306-318 peptide. Data are representative of two independent experimental repeats (n = 2). (D) SPR analysis showing concentration-
dependent binding (57 μM to 0.11 μM) of LAG-3:Fc to HLA-DR1 covalently-linked to CLIP and produced in sf9 insect cells. Data are representative
of two independent experimental repeats (n = 2).
covalently linked CLIP construct in sf9 insect cells) (Fig. 3D). The
interaction was characterized by rapid binding kinetics (kon and
koff) in line with previously published interactions between HLA
molecules and both TCRs and co-receptor molecules [34].
To determine the monovalent affinity between LAG-3 and
pHLA-II, we first explored the valency exhibited by the dimeric
LAG-3:Fc fusion protein. To this end, various simultaneous
kon/koff modeling curves were applied to observed binding sen-
sograms at LAG-3:Fc concentrations of 0.1–7 μM and compared
for visual goodness-of-fit as well as analysis of χ2 and residual plot
parameters (Supporting Information Fig. S2A). No model demon-
strated perfect matching to observed data across multiple concen-
trations. However, kinetic data were best described by the biva-
lent analyte model of binding by satisfying multiple analyzed ana-
lyte concentrations. Bivalent analytes can exhibit altered kinetics
at different analyte concentrations making fitting global parame-
ters that satisfy multiple protein injection concentrations difficult.
Analysis of kinetic fitting to a single intermediate concentration
of analyte (local fitting) resulted in a similar good fit and compa-
rable kinetic parameters to those observed in global fitting (Sup-
porting Information Fig. S2B). While LAG-3:Fc binding was best
described by the bivalent analyte model, it was observed that dis-
sociation of LAG-3:Fc unexpectedly occurred with fast kinetics;
within the timescale of seconds. Such fast kinetics are atypical of
dimeric molecules binding with bivalency. To determine the rates
of monovalent and bivalent interactions to the overall observed
kinetics, the kinetic parameters of bivalent binding (kon1, koff1,
kon2, and koff2) were calculated from kinetic fits (Table 1). From
this analysis, the affinity constant KD1, which defines the monova-
lent component of the interaction was calculated. Analysis of the
kinetic derived equilibrium dissociation constants suggested that
the contribution of bivalent effects to observed LAG-3:Fc binding
was minimal, as signified by a higher calculated dissociation con-
stant for the bivalent component (KD2) and fast off-rates (Table 1).
As a result, the observed kinetics were dominated by 1:1 binding
with minimal contribution of bivalency.
In order to deduce the monovalent affinity for LAG-3:Fc bind-
ing to pHLA-DR1, we attempted to remove the weak component
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Local 7.1 1190 6.6 39.6 7.24 × 104 0.439 156.6 4.30 × 10−3 6.06 × 10−6 2.75 × 10−5 6.06
Global 0.1 – 7.1 962 4.6 – 16.9 27.6 5.22 × 104 0.380 96.9 4.10 × 10−3 7.28 × 10−6 4.23 × 10−5 7.28
[Analyte] = Concentration of injected LAG-3:Fc analyte, RU = Response units,
Rmax = Maximum analyte binding capacity in RU, RI = Bulk refractive index effect in RU,
χ2 = ∑ (observed−expected)2expected ; lower χ2 values indicate better model fitting.
*Kon2 was converted to M−1 s−1 via the following equation: kon2 (M−1 s−1) = kon2 (RU−1 s−1) × 100 × molecular weight of LAG-3:Fc [44,45].
KD1= the affinity equilibrium dissociation constant (monovalent component).
KD2 = the affinity equilibrium dissociation constant (bivalent component).
of bivalent binding by lowering the density of ligand on the chip
surface. We also attempted to immobilize LAG-3:Fc on the chip
surface, but without success. Lower ligand density increases the
spatial distance between molecules and, as a result, reduces the
availability of a second ligand species to engage with bivalency.
The presence of bivalency can therefore also be confirmed by the
increase in ligand density, increasing bivalent binding and conse-
quently increasing observed avidity effects (Supporting Informa-
tion Fig. S3A). Different concentrations of pHLA-DR1 was immo-
bilized to flow cells of the same sensor chip such that the effect
of LAG-3:Fc analyte binding to low, intermediate, and high ligand
densities could be studied (Supporting Information Fig. S3B and
C). In agreement with described kinetic modelling of LAG-3:Fc
binding, increase in ligand density prolonged binding kinetics by
lengthening the observed Koff of LAG-3:Fc. Similarly to previous
kinetic analysis, at the highest ligand density tested, LAG-3:Fc did
not exhibit antibody-like Koff, again suggesting that LAG-3:Fc did
not efficiently engage with multiple pHLA-DR1 molecules. Exper-
iments at low ligand concentration (244 response units of pHLA-
DR1) displayed fast kinetics and no extension of dissociation. As
a result, LAG-3:Fc binding at low ligand density exhibited one-to-
one monovalent binding behavior. Indeed, low ligand density sen-
sograms did not adhere to a bivalent kinetic model fitting (data
not shown).
As SPR data at low ligand density exhibited monovalent bind-
ing, a steady state derived affinity could be calculated. Using this
described steady-state analysis, the monovalent affinity of LAG-
3 binding to pHLA-DR1 was KD = 13.1 μM (Fig. 4A). Since the
lowest ligand density tested may still contain contributions from
bivalent binding, the calculated monovalent KD value under the
assumption of one-to-one binding may over-calculate the mono-
valent affinity, i.e., the monovalent affinity might appear artifi-
cially stronger due to a remaining contribution from bivalency. In
order to further validate the assumption of one-to-one binding,
SPR data at intermediate density was analyzed by kinetic analy-
sis. Global and local fitting of the bivalent analyte model revealed
an equilibrium dissociation constant (KD1) for the monovalent
affinity for LAG-3 to pHLA-DR1 within a similar range as shown
by equilibrium binding analysis (KD1 = 6.9–7.3 μM) (Fig. 4B).
This similar kinetic rate derived affinity constant validates the
assumption that low ligand density steady-state analysis was pre-
dominated by monovalent binding. Together, these data therefore
define the affinity of LAG-3 for pHLA-DR1 loaded with the high
affinity peptide HA306-318 to be ∼6.9–13.1 μM at 25°C.
pHLA-DR1 multimers bind to LAG-3+ cells at the cell
surface
In order to confirm the molecular interaction of LAG-3 and pHLA-
II on the surface of LAG-3 expressing cells, a stably expressing
LAG-3+ JRT clone (JRT LAG-3+ C8; derived from J.RT3-T3.5
Jurkat cells) was produced (Supporting Information Fig. S4A and
B). JRT WT, JRT LAG-3+ C8 cells, and the MOLT-3 cell line (an
LAG-3- CD4+ control) were analyzed for TCR, LAG-3, and CD4
expression demonstrating LAG-3 expression only on JRT LAG-3+
C8 cells and CD4 expression only on MOLT-3 cells (Supporting
Information Fig. S5). JRT WT and JRT LAG-3+ C8 cells were
stained using PE labeled pHLA-DR1 dextramers using a protocol
optimized for low affinity interactions [35]. Staining of JRT
LAG-3+ C8 cells with HLA-DR1 multimers loaded with HA306-318
peptide resulted in a modest detection of LAG-3 replete cells com-
pared to both FMO and pHLA-A2 multimer controls, while JRT
WT cells exhibited no staining (Fig. 5A and B). Staining of LAG-3
replete cells with pHLA-DR1 multimers resulted in 19% of cells
exhibiting detectable staining compared to background levels. To
ensure the observed multimer staining did not arise due to mul-
timer deposition on dead cells, all experiments described were
gated on live lymphocyte cells by live/dead staining (Fig. 5C).
Despite the observed staining of JRT LAG-3+ C8 cells by pHLA-
DR1 multimers, such staining was poor compared to staining
of a previously published HLA-DR1-HA306-318-specific cognate
T cell clone (DC-C10) [36], where 99% of cells were detected
as multimer+ (Fig. 5D). In order to confirm that the observed
staining of LAG-3+ cells by pHLA-DR1 multimers was mediated
by LAG-3, the effect of the LAG-3 blocking antibody, clone
17B4, on pHLA-DR1 multimer staining was assayed. Indeed,
pre-incubation of JRT LAG-3+ C8 cells before multimer stain-
ing abrogated the shift in fluorescence intensity observed
when staining with pHLA-DR1 multimers (Fig. 5E). To confirm
antibody blockade had no effect on pHLA-A2 multimer staining,
corresponding blockade experiments were also performed on
such controls and resulted in no significant impact on background
staining (Fig. 5F). Moreover, an irrelevant antibody (αCD4) was
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Figure 4. (A) Top left: SPR analysis of LAG-3:Fc binding to pHLA-DR1 immobilized at low (244 RU) ligand concentration. Top right: Steady-state
analysis of LAG-3:Fc binding to pHLA-DR1 at low ligand concentrations analyzed from sensograms shown in A by plotting RU increase from baseline
during steady-state (30 seconds into injections) against concentration of LAG-3:Fc.Data are representative of two independent experimental repeats
(n = 2). Bottom: Schematic representation of LAG-3:Fc binding to a single pHLA-DR species at low ligand density and the applied steady-state 1:1
binding model by which a monovalent affinity (KD) was calculated. (B) Top left: Global fit analysis of reference subtracted sensograms of LAG-3:Fc
(0.1–7 μM) binding to immobilized (525 RU) pHLA-DR1 fitted with a bivalent analyte model. Observed sensograms are shown as grey solid lines,
fitted curves as black dashed lines with inset χ2 value and kinetic derived dissociation affinity constant KD1. Corresponding curve fit residual plots
are shown below each fit. Top right: Local fit analysis of the reference subtracted sensogram describing LAG-3:Fc binding at 7 μM to immobilized
pHLA-DR1. Data are representative of two independent experimental repeats (n = 2). Bottom: Schematic representation of LAG 3:Fc binding with
bivalency at intermediate ligand density. The applied bivalent binding model is shown, highlighting the monovalent component of the binding
model by which a monovalent affinity (KD1) was calculated.
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Figure 5. (A) 2D Flow cytometry plots of pHLA-multimer staining of JRTWT cells (left) and JRT LAG-3+ C8 cells (right) with pHLA-A*02:01 multimers
(grey) or pHLA-DR1 multimers (black). Inset numbers = percentage multimer+ cells. Data are representative of three independent experimental
repeats with one sample per experiment. (B) Flow cytometry histograms of pHLA-multimer staining as in (A). Geometric mean fluorescent intensity
(gMFI) values are indicated in the inset. Data are representative of three independent experimental repeats with one sample per experiment. (C)
Example gating strategy of lymphocyte gate and live L/D-A- cells used for all flow cytometry analysis. Example shown is JRT LAG-3+ C8 cells stained
with pHLA-DR1multimers. (D) 2D Flow cytometry plot of cognate CD4+ T cell clone (DCD10) stainingwith pHLA-DR1multimers used in experiments
described. Cognate (DR1PKY) and irrelevant (DR1irrel) multimer stains are shown. Data are representative of two independent experimental repeats
with one sample per experiment. (E) Flow cytometry histograms of pHLA-multimer staining of JRT WT cells (left) and JRT LAG-3+ C8 cells (right)
stained with pHLA-DR1 multimers pre-blocked with unconjugated anti-LAG-3 mAb clone 17B4 (orange; dashed) or media control (black). Data
are representative of two independent experimental repeats with one sample per experiment. Data shown in (B) and (E) were performed as a
single experiment and are depicted separately for clarity. (F) FMO subtracted quantification of gMFI in experiments described in (E). Data are
representative of two independent experimental repeats with one sample per experiment. (G) Quantification of pHLA-DR1 binding to JRT LAG-3+
C8 cells pre-incubated with control (media), irrelevant mAb (irrelevant; anti-CD4) or anti-LAG-3 mAb (17B4). Percentage binding normalized to
background subtracted gMFI observed for control blockade of pHLA-DR1 binding. Data are representative of two independent experimental repeats
with one sample per experiment. (H) Left: 2D Flow cytometry plots of pHLA-II-multimer staining of LAG-3- CD4+ MOLT-3 cells with pHLA-A*02:01
multimers (grey), or pHLA-DR1 multimers (black). Inset numbers = percentage multimer+ cells, color coded as described. Data are representative
of two experimental repeats with one sample per experiment. Right: Staining of LAG-3- CD4+ MOLT-3 cells with either pHLA-A*02:01 or pHLA-DR1
multimers. Data are a representative of two experimental repeats with one sample per experiment. All data in graphs are single gMFI values from
a representative example experiment.
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not able to abrogate the binding of pHLA-DR1 multimers to
JRT LAG-3+ C8 cells (Fig. 5G). Since CD4 also binds to pHLA-II
molecules, albeit via a very weak interaction [17], it was reasoned
that a similar staining of CD4+ cells by pHLA-II multimers may be
observed. The CD4+ LAG-3- MOLT-3 cell line, however, showed
no significant detection of multimer+ cells using pHLA-DR1
multimers (Fig. 5H).
Discussion
LAG-3 is a target for the next wave of checkpoint immunother-
apies, but little is known about the biology of its ligands, and
how this relates to its function. Previous evidence has suggested
pHLA-II as a receptor for LAG-3 [8,16,18,19,22,23], but the
cell-adhesion molecule LSECtin/CLEC4G [21], Galectin-3 [37],
α-synuclein [38], and fibrinogen-like protein-1 [20], have also
been proposed as LAG-3 ligands. Here, we used a cutting-edge
microbead interaction assay (AlphaScreenTM), combined with
SPR analysis and cellular flow cytometry to characterize the direct
protein–protein interaction between LAG-3 and pHLA-II using a
well characterized bivalent LAG-3:Fc fusion protein [19]. SPR and
AlphaScreenTM analyses demonstrated that LAG-3 bound inde-
pendently of the HLA allele tested (HLA-DR1 and HLA-DR4) and
the presented peptide (HA306-318 and CLIP) with an affinity (KD)
of 6.9–13.1 μM. This affinity is comparable to that of TCR engage-
ment of pathogen-derived peptides and is higher than average
TCR-pHLA-II binding [30]. However, this μM affinity is several log
orders of magnitude weaker than the calculated avidity of dimeric
LAG-3 binding in indirect cell surface experiments (KD = 60 nM
at 37°C) [19]. Recent evidence suggests that LAG-3 might selec-
tively bind to stable pHLA-II complexes, but not unstable pHLA-II
complexes, via a conformationally dependent mechanism [11].
Although we did not test any unstable pHLA-II complexes in our
study (HA306-318 is known to be a strong HLA-DR1 binder, and
CLIP was stabilized via a covalent linker), our data showing that
LAG-3 binding was unaffected by these two stable peptides is in
line with this notion.
Despite the weak affinity, these studies show LAG-3 binds
pHLA-DR1 at a significantly stronger affinity than the CD4 co-
receptor, for which the solution affinity has been estimated as
2.5 mM [17]. As LAG-3 binding to pHLA-II molecules has been
shown to block consequent CD4 binding at the cell surface [19],
competition between LAG-3 and CD4 for pHLA-II binding would
favor engagement by LAG-3, potentially contributing to LAG-3
mediated T cell inhibition. It is noteworthy that the LAG-3 affin-
ity for pHLA-II reported here (KD = 6.9–13.1 μM) is similar to
that of the pHLA-I co-inhibitory receptor, ILT2 (KD = 7 μM) [26],
which interferes with pHLA-I restricted T cell function [39]. We
also demonstrated that pHLA-DR1 multimers weakly stain LAG-
3+ cells. Such staining could not be attributed to TCR binding
due to the lack of TCR-β chain expression in the JRT3 T3.5 Jurkat
cell line as confirmed by minimal staining of JRT LAG-3+ C8 cells
with a pan-αβ TCR antibody. The observed staining was instead
shown to be LAG-3 dependent by the blockade of multimer stain-
ing by the 17B4 clone αLAG-3 antibody. Although 100% LAG-3
expression was observed for the JRT LAG-3+ C8 cells, only a frac-
tion of cells were detected by pHLA-DR1 multimers. Despite the
relatively weak (compared to pHLA-II staining of TCRs) staining
we observed, these data have important implications for CD4+ T
cell biology experimental design in order to prevent misdetection
of LAG-3+ cells as perceived antigen-specific multimer+ cells.
Importantly, staining of LAG-3+ cells with pHLA-DR multimers
was far weaker than the staining we observed on T cells using
cognate peptide loaded pHLA-DR multimers. This was regardless
of the stronger binding affinity of the pHLA-II-LAG-3 interaction
compared to the TCR-pHLA-II interaction. As there is evidence
that LAG-3 forms dimeric molecules at the cell surface [40], these
findings raise interesting questions over the role of LAG-3 dimer-
ization contributing to an increase in functional potency. For CD4,
despite a weak affinity, pHLA-II-CD4 binding maintains TCR phos-
phorylation at an active basal level by recruitment of Lck and thus
poises T cells for cognate TCR-pHLA engagement [17]. Since LAG-
3 also exhibits fast kinetic binding to pHLA-II, parallels between
LAG-3 and CD4 co-receptor maintenance of antigen specificity
may exist. Indeed, surface bound LAG-3 mediated inhibition of
DC maturation has been shown to be antigen specific and require
TCR-pHLA-II engagement by LAG-3 expressing Tregs [41]. Thus,
the interaction between LAG-3 and pHLA-II at the cell surface may
be tuned such that ligand discrimination is maintained. However,
the role that LAG-3 plays on activated human T cells is poorly
understood. Consequently, further knowledge of LAG-3 signaling
is required to understand how this observed affinity for pHLA-II
affects LAG-3 mediated T cell homeostasis, as well as considering
the potential role of other LAG-3 ligands [20,21,37,38].
In summary, we show that LAG-3 directly interacts with dif-
ferent HLA-II alleles with low micromolar affinity, independently
of the presented peptide, HLA-II allele and glycosylation state of
the pHLA-II molecule. As a result, these data add evidence to the
model where LAG-3 outcompetes CD4 for pHLA-II binding during
LAG-3 mediated T cell suppression. Our findings have interesting
implications for LAG-3 mediated T cell biology, which is a major
focus for the development of novel checkpoint immunotherapies.
Materials and methods
Production of soluble pHLA-DR1 and LAG-3:Fc
Soluble pHLA-DR1 was either refolded from recombinant DR1α
and DR1β chains produced in the BL21(DE3) strain of E. coli
[29], or generated in Spodoptera frugiperda (sf9) insect cells using
the BaculoDirectTM expression system (ThermoFisher Scientific)
[30] as previously described. pHLA-DR1 molecules were biotiny-
lated by inclusion of a C-terminal AviTAGTM biotinylation signal
sequence on the DR1α chain that was biotinylated using a BirA
biotin-protein ligase kit (Avidity) [36]. A fusion protein of the
four extracellular domains of LAG-3 and the Fc domain of IgG
(LAG-3:Fc) was produced in CHO cells as previously described
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[19]. LAG-3:Fc was stable in a solution of 20 mM sodium citrate,
86 mM sodium chloride, 100 mM L-arginine, 0.02% Tween-20,
pH 7.4 with citric acid (TBSB buffer) at concentrations of up to
30 mg/mL.
AlphaScreenTM analysis
Due to the nature of the AlphaScreenTM bead-based proximity
assay (Perkin Elmer), optimal protein concentration that results
in optimal coating of the bead is unique to each protein and
bead combination. Therefore, protein cross titrations were per-
formed. For each protein individual 4× working solutions were
prepared using AlphaLISATM buffer. These were used to produce
a serial dilution for each protein sample. Each dilution series also
included an AlphaLISATM buffer alone in order to measure back-
ground signal. The protein dilutions (10 μL of each), were loaded
into a 96-well half area opti-plate. The plate was sealed and incu-
bated for 1 h at room temperature. The 4× working solution (20
μg/mL final concentration) of protein A acceptor beads and strep-
tavidin donor beads weres prepared using AlphaLISATM buffer
keeping donor beads protected from light. Equal volume of each
bead solution was mixed and 20 μL of this combined bead solu-
tion was loaded into all wells containing pre-incubated protein
samples. The plate was then re-sealed and incubated at room tem-
perature for 1 h. The plate seal was then removed, and the plate
read by an En-vision plate reader (Perkin Elmer).
Anti-LAG-3 fab fragment blocking assay
Direct blocking assays were conducted for the LAG-3:Fc-pHLA-
DR1-biotinylated AlphaScreenTM assay. Due to the use of protein
A beads to capture LAG-3:Fc, the antibodies (αLAG-3 4B1 in house
generated and αHLA-DR1 L243 (Biolegend)) were first papain
digested using a PierceTM Fab Preparation Kit (ThermoFisher Sci-
entific) according to the manufactures instruction, to remove anti-
body Fc fragments. To prevent the antibodies binding to the pro-
tein A beads, serial diluted fab fragments were then added to fixed
concentrations of LAG-3:Fc and pHLA-DR1. AlphaScreenTM assays
were performed as described above but using 5× working solu-
tions to account for addition of 10 μL of antibody fab fragment
samples to the protein incubation step.
Analysis of LAG-3-pHLA-DR1 binding via SPR
LAG-3:Fc sample was gel filtrated into fresh TBSB buffer the day
of SPR experiments using a Superdex S200 10/300 column and
ÄKTA Pure fast protein liquid chromatography system (GEHealth-
care Life Sciences). Analysis of LAG-3:Fc-pHLA-DR1 binding was
performed on a BIAcore T200 instrument (GE Healthcare Life Sci-
ences). All experiments were performed at 25°C in TBSB buffer.
Prepared biotinylated pHLA-DR molecules were immobilized to
covalently linked streptavidin coated CM5 sensor chips prepared
as previously described [42]. Biotinylated pHLA-DR molecules
were bound to the chip surface at a flow rate of 10 μL/min. LAG-
3:Fc molecules were twofold serially diluted and sequentially
injected at 30 μL/min (30 s association, 300 s dissociation) over
the pHLA-DR chip surface. Recorded sensograms were reference
subtracted against a control flow cell of HLAA*02:01-hTERT540-548
after confirmation as a suitable non-binding control ligand. Senso-
grams were analyzed using BIAevaluation version 4.1 (GE Health-
care Life Sciences) and plotted using GraphPad Prism version 5
(GraphPad Software, Inc). Kinetic analyses of LAG-3:Fc binding
were performed using the simultaneous kon/koff fitting function
of the binding model specified. Equilibrium analyses were per-
formed using nonlinear regression least squares ordinary fit of the
one-site specific binding model using GraphPad Prism version 5.
Generation of LAG-3+ Jurkat cells
The full length sequence of human LAG-3 (Uniprot: P18627)
flanked by a 5’ XbaI restriction site (TCTAGA), Kozak sequence
(GCCGCCACC) and start codon (ATG) and a 3’ XhoI restriction
site (CTCGAG) was codon optimized for human expression and
cloned into the pELNsxv third generation lentiviral transfer vector
(kindly provided by Prof. James Riley, University of Pennsylvania)
containing a self-cleaving P2A linked rat CD2 (rCD2) expression
cassette within the multiple cloning site (P2A.rCD2.pELNsxv).
LAG-3 encoding lentiviral particles were generated in HEK 293T
cells (ATCC® CRL-3216TM) by calcium chloride transfection of
LAG-3.P2A.rCD2.pELNsxv with the lentiviral packaging plasmids
pMD2.G (Addgene plasmid #12259), pMDLg/pRRE (Addgene
plasmid #12251), and pRSV-Rev (Addgene plasmid #12253) that
were gifts from Didier Trono [43]. J.RT3-T3.5 Jurkat cells (JRT)
(ATCC® TIB-153TM) were transduced with LAG-3.P2A.rCD2
lentiviral supernatents by incubating 2 × 105 cells seeded in a 48-
well plate and incubating overnight at 37˚C and 5% CO2. Trans-
duction of JRT cells was assessed by fluorescent antibody staining
of rCD2 (PE-conjugated clone OX-34; Biolegend) and LAG-3 (PE-
conjugated goat polyclonal; R&D Systems) using a BD FACSCanto
II flow cytometer. Data were analyzed using FlowJo (Tree Star
Inc.). Transduced JRT cells were subsequently cloned using limit-
ing dilution to obtain a clonal LAG-3 expressing population (JRT
LAG-3+ C8).
pHLA-DR multimer staining of LAG-3+ Jurkat cells
Multimer staining was performed on JRT LAG-3+ C8, JRT WT,
and MOLT-3 cells (ATCC CRL-1552TM). TCR (FITC-conjugated
clone IP26; BioLegend), LAG-3 (FITC-conjugated clone 17B4;
Enzo Life Sciences), and CD4 (APCy-conjugated clone VIT4; Mil-
tenyi Biotec) expression by JRT LAG-3+ C8, JRT WT, and MOLT-3
cells was characterized as single stains prior to multimer staining
experiments. PE-conjugated pHLA-DR dextramers (Immudex)
were prepared as previously described [36]. Prepared multimers
were used to stain JRT LAG-3+ C8, JRT WT, and MOLT-3 cells
© 2020 The Authors. European Journal of Immunology published by
Wiley-VCH GmbH
www.eji-journal.eu
340 Bruce J. MacLachlan et al. Eur. J. Immunol. 2021. 51: 331–341
using a protocol optimized for low affinity interactions that
included pretreatment of cells with the protein kinase inhibitor
dasatinib and boosting staining with unconjugated anti-PE (clone
PE001; BioLegend) [35]. For antibody blocking experiments, cells
were plated and washed then incubated with 10 μg/mL uncon-
jugated anti-LAG-3 (clone 17B4), irrelevant control anti-CD4
(clone VIT4), or media for 1 h on ice prior to multimer staining.
Cells were stained for viability using LIVE/DEAD® Fixable Violet
Dead Cell Stain (Thermo Fisher Scientific).
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